drugset
drugset / Trial / NCT03215381

AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers

NCT03215381 ↗

Phase 1 Completed 8 enrolled AstraZeneca Karolinska Institutet, Quintiles IMS · collab
NaSingle-groupOpen-labelOther

Summary

This is an open-label, single centre exploratory study to analyse brain exposure of AZD1390 in healthy volunteer males.

Timeline

Start
2017-10-10
Primary completion
2018-02-19
Completion
2018-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1390 Small molecule 10 ug —

Indications

No indication recorded.